SOUTH SAN FRANCISCO, Calif., Aug. 29 /PRNewswire-FirstCall/ -- Exelixis, Inc. announced today that it will hold a webcast briefing for analysts and investors in conjunction with the International Association for the Study of Lung Cancer’s (IASLC) 12th World Conference on Lung Cancer. The webcast will be held on Wednesday, September 5, 2007, at 5:00 a.m. PDT/8:00 a.m. EDT. During the webcast, Exelixis management will discuss data from a Phase 2 trial of XL647 in non-small cell lung cancer patients presented at the Conference.
The webcast may be accessed in the Event Calendar page under Investors at http://www.exelixis.com.
An archive of this webcast will be available until 8:59 p.m. PDT/11:59 p.m. EDT on October 5, 2007. Access numbers for this replay are 888-286-8010 (domestic) and 617-801-6888 (international). The replay passcode is 18807116.
About Exelixis
Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis’ broad product pipeline includes investigational compounds in phase 2 and phase 1 clinical development for cancer and renal disease. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb Company, Genentech, Wyeth Pharmaceuticals and Daiichi-Sankyo. For more information, please visit the company’s web site at http://www.exelixis.com.
Exelixis, Inc.
CONTACT: Charles Butler, Director, Investor Relations, +1-650-837-7277,cbutler@exelixis.com, or Hal Mackins, +1-650-837-7012, both of Exelixis,Inc.
Web site: http://www.exelixis.com/
